477 related articles for article (PubMed ID: 10186943)
1. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
2. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
3. Comparative profile of tizanidine in the management of spasticity.
Lataste X; Emre M; Davis C; Groves L
Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
[TBL] [Abstract][Full Text] [Related]
4. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
[TBL] [Abstract][Full Text] [Related]
5. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
Wallace JD
Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
7. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
Vakhapova V; Auriel E; Karni A
Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
[TBL] [Abstract][Full Text] [Related]
8. [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].
Pellkofer M; Paulig M
Med Klin (Munich); 1989 Jan; 84(1):5-8. PubMed ID: 2645508
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
Medici M; Pebet M; Ciblis D
Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
[TBL] [Abstract][Full Text] [Related]
11. An approach to switching patients from baclofen to tizanidine.
Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
[TBL] [Abstract][Full Text] [Related]
12. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity.
Delwaide PJ
Ann Neurol; 1985 Jan; 17(1):90-5. PubMed ID: 3985591
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial.
Bresolin N; Zucca C; Pecori A
Adv Ther; 2009 May; 26(5):563-73. PubMed ID: 19458926
[TBL] [Abstract][Full Text] [Related]
16. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
17. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
[TBL] [Abstract][Full Text] [Related]
18. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy.
Roussan M; Terrence C; Fromm G
Pharmatherapeutica; 1985; 4(5):278-84. PubMed ID: 3906673
[TBL] [Abstract][Full Text] [Related]
19. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
Stien R; Nordal HJ; Oftedal SI; Slettebø M
Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
[TBL] [Abstract][Full Text] [Related]
20. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
